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Background: HPV vaccines have demonstrated high efficacy in clinical trials against 
cervical lesions and infections by HPV vaccine types 16 and 18.  Together these two 
types are responsible for approximately 70% of cervical cancer.  Data on HPV vaccine 
effectiveness in general populations is limited.  
 
Methods: Surveillance data monitoring high-grade cervical lesions in Connecticut was 
used.  Medical records were reviewed and patients were interviewed to ascertain HPV 
vaccine history.  Patients’ biopsy specimens were typed to determine the presence of 
vaccine or non-vaccine type HPV.  Odds ratios were determined using logistic 
regression, adjusting for age at diagnosis, grade of cervical lesion, race/ethnicity, and 
insurance type.      
 
Results: From 2008-2012, 788 women with known vaccine status and typed biopsy 
specimens were analyzed.   8.9% of women received at least one vaccine dose.  
Adjusted vaccine effectiveness for at least one dose was estimated to be 53%.  Vaccine 
type HPV was strongly associated with higher grade cervical lesions, but other 
statistically significant associations were not found. 
 
Conclusions: The data suggests that HPV vaccination provides protection against 
vaccine type high-grade cervical lesions in women.  Although these results are 
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Human papillomavirus (HPV) is the most common sexually transmitted infection 
in the United States [1].  The overall prevalence for genital HPV infection is 26.8% for 
American women between 14 and 59 years old, with the highest prevalence in women 
20-24 years old (44.8%) [2].  There are over 100 human papillomavirus types that infect 
humans [3].  Of these, more than 40 types of HPV that infect the anogenital tract have 
been identified [4].  Most HPV infections are cleared without treatment in about 12 
months, nononcogenic strains clearing faster than oncogenic strains [5].  Persistent 
infections that do not clear can progress to precancerous cervical lesions and cervical 
cancer.  HPV is detected in over 99% of cervical carcinomas and is a necessary cause 
of cervical cancer [6].  HPV is also associated with a high number of vaginal, anal, 
vulvar, and penile cancers, as well as various head and neck cancers and genital warts 
[7]. 
  HPV types can be categorized as high risk, probable high risk, and low risk [4].  
Low risk types are generally associated with genital warts and high risk with cervical 
lesions and cancer.  Worldwide, approximately 70% of invasive cervical cancer is 
caused by HPV types 16 and 18 [8].  Gardasil, a quadrivalent vaccine that protects 
against high risk types 16 and 18 and low risk types 6 and 11 was approved by the 
Food and Drug Administration (FDA) for use in females age 9-26 in 2006 [9].  In 2009, a 
bivalent vaccine that protects against types 16 and 18, Cervarix, was approved for 
females age 10-25 [10].  The current Advisory Committee for Immunization Practices 
(ACIP) recommendations are routine vaccination for females age 11-12 with either the 
quadrivalent or bivalent vaccine and for males age 11-12 with the quadrivalent vaccine 
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only [9, 11, 12].  Permissive or catch-up vaccination is recommended up to age 26.  
Both the quadrivalent and bivalent vaccines have shown over 95% efficacy in clinical 
trials for prevention of cervical infections in HPV-naïve women [13-16].  The bivalent 
vaccine has also shown cross-protective efficacy against four oncogenic non-vaccine 
types and three low risk types [17, 18]. 
In 2012, 34.5% of women age 19-26 in the United States were estimated to have 
received at least one dose of HPV vaccine [19].  This was a slight increase from 29.5% 
coverage in 2011 and 20.7% coverage in 2010 [20, 21].  Among girls age 13-17, the 
estimated coverage for one dose or more has increased from 25.1% in 2007 to 53.8% 
in 2012 [22].  The 2012 coverage for the state of Connecticut of 57.6% was slightly 
higher than the national average, however there was no increase from 60.5% estimated 
coverage in 2011 [23, 24].   
Cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) are 
precancerous cervical lesions caused by HPV.  These lesions do not necessarily 
progress into cancer and some may regress [25, 26].  The high risk strains are usually 
associated with these lesions, but low risk strains can also cause CIN 1 and CIN 2 [27].  
CIN is 1 referred to as a low-grade lesion, while CIN 2, CIN 3, and AIS are considered 
high-grade.  CIN 2 is the current recommended treatment threshold, but observation is 
the preferred course of action for younger women who are more likely to have natural 
regression [28].  In 2010, screening guidelines changed to no longer screen women 
under the age of 21 because of the rarity of cervical cancer in women that age and high 
probability of regression [29].  Cervical cancer incidence and mortality has overall 
declined greatly in developed nations since the 1960s and 1970s due to screening 
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programs and improved treatment.  However, there are recent increases in young 
women in some countries, which may be a result of generational differences in sex 
habits [30]. 
Evidence of overall vaccine impact can currently be best detected through 
prevalence of vaccine type HPV and diagnoses of genital warts, while vaccine impact 
on high-grade cervical lesions and cancer will take longer to fully demonstrate because 
these conditions take years to decades to develop [31].  Reports of reduced prevalence 
of vaccine type HPV and genital warts in the United States and other countries provides 
early evidence of vaccine impact [32].  Previous HPV-IMPACT results also suggest 
vaccine impact; a significantly lower proportion of CIN2+ caused by vaccine type HPV 
was found in women who were vaccinated greater than 24 months before their trigger 
Pap [33].  
In Australia, an extensive vaccination program began in 2007 for in school routine 
vaccination for girls 12-13 and catch-up vaccination for girls 13-17, along with 
community catch-up vaccination for women 18-26.  The incidence of high-grade cervical 
lesions in females under age 18 was found to be significantly reduced after induction of 
this program; however, incidence for females in other age groups did not change 
significantly [34].  Evidence for quadrivalent vaccine effectiveness against cervical 
abnormalities has begun to emerge from this program in Australia as well.  A case-
control study using anonymous, linked registry data for vaccination status and 
development of cervical abnormalities detected upon first Pap screening found 
statistically significant protection against these abnormalities in young women [35].             
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The Connecticut HPV-IMPACT group has already reported significantly declining 
rates of high-grade cervical lesions in the state for women ages 21-24 years [36].  The 
same analysis also found significant declines in census tracts with lower proportions of 
the population black, Hispanic, or living below the federal poverty level and in nonurban 
areas.  Another study by the group found black race, Hispanic ethnicity, and higher 
area-based poverty to be associated with lower likelihood of vaccine-type HPV [37].  
This suggests that the vaccine may have lower impact among these women.  The group 
has published other findings on racial/ethnic and economic disparities in HPV 
vaccination and high-grade cervical lesion diagnoses [38-40]. 
Pooled analysis of quadrivalent vaccine efficacy from three clinical trials 
demonstrates over 95% efficacy against high-grade cervical lesions for per-protocol 
treatment [13].  However in these trials participants were excluded if they had prior 
abnormal Pap results, over four lifetime sex partners, or prior confirmed HPV disease.  
This does not accurately represent actual populations of women at risk for high-grade 
cervical lesions.  Similarly high efficacy was found for the bivalent vaccine in clinical 
trials, and in addition women were included irrespective of their HPV status and 
cytology, but were excluded if they had more than six lifetime sex partners or previous 
colposcopy [14].  This is more inclusive, but still not fully representative and may not be 
as applicable, as almost all HPV vaccines administered in the United States from 2006-
2010 were the quadrivalent vaccine [41].   
In 2010, over 11,800 women were diagnosed with cervical cancer in the United 
States and over 3,900 women died from the disease [42].  Over one million women are 
diagnosed with low-grade cervical lesions each year and approximately 500,000 are 
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diagnosed with high-grade lesions [28, 43].  The cost for one instance of these 
diagnoses can range from approximately $1,000 for CIN1 to over $3,000 for CIN3, and 
overall cost of management of precancerous cervical lesions was approximately 17% of 
total cervical HPV related costs for one health plan [44].  The estimated annual baseline 
cost per case for cervical cancer was $38,800 in 2010 US dollars [45].  Diagnoses with 
these conditions can also have negative psychological impact such as fear of cancer, 
infertility, or loss of sexual function; depression; sleep disturbance; anxiety; and 
embarrassment [46, 47]. 
Given the physical, financial, and psychological burden of HPV related cervical 
lesions, there is a definite need for preventative action.  HPV vaccines have shown very 
high efficacy in clinical trials, but at this time there is limited data on the effectiveness of 
these vaccines at preventing vaccine type lesions in real world populations.  This 
analysis attempts to estimate vaccine effectiveness in the entire population of young 
women in New Haven County, Connecticut using surveillance data.  This study aims to 
fill the knowledge gap on HPV vaccine effectiveness against high-grade cervical lesions 




Surveillance System  
 
In 2008, the Centers for Disease Control and Prevention (CDC) began monitoring 
HPV vaccine impact through the Emerging Infections Program (EIP) network using 
population-based surveillance of high-grade cervical lesions [48].  On January 1st, 2008, 
the Connecticut Department of Public Health designated CIN 2 and higher and AIS as 
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mandatory reportable diseases in the state [49].  All pathology labs in the state are 
required to report these diagnoses.  The reports contain the diagnostic information and 
patient demographics.  Reports were reviewed by EIP staff for eligibility and accuracy 
and then entered into a database.   
 
Medical Record Review and Patient Interviews 
Enhanced surveillance was conducted for New Haven County residents between 18 
and 39 years old at the time of diagnosis.  EIP staff reviewed available medical records 
of these patients from the provider who performed the biopsy that produced the 
diagnosis.  Medical records were reviewed for HPV vaccination status, cervical cancer 
screening history (including the date and results of the abnormal “trigger” Pap that lead 
to the biopsy and diagnosis), as well as demographic and contact information that may 
have been missing from the initial report.  EIP staff then conducted telephone interviews 
with these patients which touched on similar information to the medical record review.  
Patients were asked if they received the vaccine.  Patients who reported receiving the 
vaccine were then asked if it was the quadrivalent or bivalent vaccine and when and 
from which provider they received each dose.  All patients were then asked 
demographic questions concerning race, ethnicity, and type of insurance at the time of 
diagnosis.   
Vaccination history was verified with providers for patients who reported being 
vaccinated.  The Connecticut HPV-IMPACT group has previously analyzed the 
concordance of vaccination history from patient interviews and medical records [50].  
Concordance of vaccination history was found to be relatively high at 83%, with 96% 
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sensitivity (percentage of women who had a history of vaccination from medical record 
and reported vaccination from patient interview) and 97% specificity (percentage of 
women who had did not have a history of vaccination from medical record and reported 
not being vaccinated during patient interview).  Although concordance was good, there 
was a high frequency of missing data.  Vaccination history was missing from 34% of 
medical records and 43% of patients could not be reached for interview.         
 
HPV Typing 
Biopsy specimens from New Haven County women age 18-39 were requested from 
pathology laboratories.  For patients with more than one available tissue block, the 
block representative of the highest grade lesion was selected by a pathologist.  
Available samples were shipped to the CDC for DNA extraction and HPV typing.  HPV 
typing was performed using polymerase chain reaction (PCR); more detailed methods 
have been described elsewhere [33, 51]. 
 
Covariates 
For this analysis, age at diagnosis was collapsed into five categories, 18-20, 21-24, 
25-29, 30-34, and 35-39.  These categories were chosen to remain consistent with 
other HPV-IMPACT analyses [51].  Race categories for patient interviews were white, 
African American, Asian, American Indian/Alaskan American, other, unknown, and 
multi-race.  Ethnicity was recorded as Hispanic, not Hispanic, or unknown.  Race and 
ethnicity were combined for this analysis as Hispanic, White (not Hispanic), African 
American (not Hispanic), other (not Hispanic), and unknown.   Asian, American 
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Indian/Alaskan American, other, and multi-race were combined into the other category 
because of low frequency.  Insurance was categorized as private, public (Medicaid, 
state assistance, or Medicare), uninsured (no coverage or self-pay), other, and 
unknown.  Diagnosis was categorized as CIN 2, CIN 2/3, CIN 3, and AIS (AIS alone or 
in conjunction with CIN 2, CIN 2/3, or CIN 3).   
 
Case Definition and Vaccination Status 
HPV type was categorized as 16/18 (vaccine type), other high risk types, possible 
high risk types, and low risk types.  Risk categories were chosen to be consistent with 
previous HPV-IMPACT analyses and current HPV epidemiologic classification [4, 51].  
Patients who tested positive for two or more different HPV types were categorized using 
a hierarchy ranked in the order of 16/18, other high risk, possible high risk, and low risk.  
Samples were categorized into the highest hierarchical group.  This was further 
collapsed into vaccine type (16/18) and non-vaccine type (other high risk, possible high 
risk, and low risk) for analysis.   
Vaccine status was defined as having at least one dose of either HPV vaccine.  
Vaccine status was categorized using time from the date of the first dose of the vaccine 
to the date of the trigger Pap that lead to the high-grade cervical lesion diagnosis.  
Vaccination status was classified as not vaccinated, vaccinated at or after trigger Pap, 
vaccinated within one year before trigger Pap, vaccinated within two years before 
trigger Pap, vaccinated within three years before trigger Pap and vaccinated three or 
more years before trigger Pap.  Patients with verified vaccination status and unknown 
trigger Pap dates were classified as vaccinated at or after trigger Pap.  Vaccine status 
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was further collapsed for the analysis so that only patients vaccinated two years or more 
before trigger Pap were considered vaccinated.  Patients vaccinated less than two 
years before trigger Pap were considered unvaccinated.  The time frame of two years or 
more was chosen based on previous HPV-IMPACT results showing significantly lower 
proportion of vaccine type HPV in women vaccinated at this time and no significant 
effect on women vaccinated less than 24 months before trigger Pap [33].   
 
Statistical Analysis 
Analysis was restricted to women with known vaccine status and known HPV type.  
If a patient had more than one high-grade cervical lesion event reported, only the first 
event was used.    Chi-square tests were used to assess associations between HPV 
type and covariates, using P<0.05 level of significance.  Unadjusted and adjusted odds 
ratios and 95% confidence intervals were estimated using logistic regression.  The 
model was reduced to adjust for covariates using backwards elimination.  Vaccine 
effectiveness was estimated using the formula (1 – adjusted odds ratio) x 100%.  All 
analyses were done using SAS statistical software (version 9.3, SAS Institute, Cary, 
NC).  Flowchart was constructed using Lucidchart (https://www.lucidchart.com/).     
 
Results 
In total, 4,327 individual women were diagnosed with high-grade cervical lesions 
in New Haven County from 2008-2014 (from the inception of surveillance to the 
beginning of data analysis).  Of these women, 2,129 had known vaccine status (1,890 
not vaccinated, 239 vaccinated) and 2,198 had unknown vaccine status.  The total 
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number of typed specimens was 1,308 (740 non-vaccine type, 568 vaccine type) for all 
women.  HPV type was not available for the remaining 3,019 women for various 
reasons, including pending specimen requests from pathology labs, samples that were 
insufficient for typing, or specimens that tested negative for all HPV types; this has been 
discussed in a previous HPV-IMPACT study [37].  Overall 520 typed specimens were 
excluded because of missing vaccine history and 169 vaccine status known women 
were excluded because of unknown HPV type.  See figure 1 for further detail on 
inclusion and exclusion frequency.   
When unknown strata were excluded, the included and excluded groups had 
similar distribution by percentage for HPV type, vaccination status, and age at first 
vaccine dose.  Age at diagnosis distribution was skewed slightly towards older age 
groups in the excluded women, with mean and median age for the included women 
(27.4±5.25, 26.6) slightly lower than the excluded women (28.3±5.16, 27.8).  There was 
a small difference between the two groups for diagnosis distribution, with higher grade 
outcomes in the excluded group.  For known race/ethnicity in the two groups, the 
percentage black and other were similar, but the included groups had a higher 
percentage white (63.38% to 50.35%) and lower percentage Hispanic (20.07% to 
33.82%).  There were also differences between the two groups for insurance type.  The 
included women had a higher percentage private insurance (73.10% to 56.95% and 
lower percentage public insurance (24.80% to 38.04%).   
A total of 788 women with known vaccine status and HPV type were used in the 
final analysis.  Typed specimens were only available for 2008-2012.  Tables 1 and 2 
present the basic demographics for the sample analyzed.  There were no statistically 
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significant differences between the vaccine type and non-vaccine type groups for 
vaccine history, age at vaccination, age at diagnosis, race/ethnicity, type of insurance, 
and year of diagnosis.  There was a significant difference between the two groups for 
cervical lesion diagnosis.  The vaccine type group had more higher grade outcomes 
than the non-vaccine type group.         
Odds ratios are presented in table 3.  Odds ratios for AIS were not calculated 
due to small sample size.  Differences in odds ratios between the unadjusted, full, and 
reduced models were small.  The most statistically significant covariate was cervical 
lesion grade in all models.  Although race/ethnicity and insurance were not found to be 
statistically significant in any model, they were kept in the final model because they 
have been found to be significantly associated with vaccine type HPV in previous HPV-
IMPACT studies [37].  The final adjusted odds ratio for vaccinated status compared to 
unvaccinated was 0.47 (95% confidence interval 0.27-0.82) for vaccine type HPV.  This 
equates to a vaccine effectiveness of 53%.       
Figure 2 displays vaccine type trends through total typed cases per year, 
regardless of vaccination history of patients, to demonstrate crude potential vaccine 
impact on type distribution over time.  Non-vaccine and vaccine types were charted as a 
percentage of total specimens with known type per year, with frequencies for each year 
tabled under the figure.  There was a large difference in number of cases for both types 
between the different years, but this is attributable to more complete data from earlier 







 A significant association was found between vaccine status and HPV type.  
Estimated vaccine effectiveness of 53% is consistent with other HPV vaccine 
effectiveness analyses, although an analysis using outcome measures of high-grade 
cervical lesion diagnoses and HPV type is not currently available to the best of our 
knowledge.  The 2013 analysis by Markowitz et al using nationally representative US 
data from the National Health and Nutrition Examination Surveys (NHANES) reported 
82% effectiveness for at least one dose of the quadrivalent vaccine against types 6, 11, 
16, and 18 infection in females 14-19 years old [41].  This study also found no 
difference in pre and post vaccine period HPV prevalence in other age groups.  The 
2014 study by Crowe et al reported 46% effectiveness against high-grade lesions and 
34% effectiveness against other abnormalities for the complete three dose series of the 
quadrivalent vaccine in females 11-27 years old in Queensland, Australia [35].  This 
study used cervical abnormalities caused by any HPV type as an outcome measure and 
specimens were not typed. 
 Of women who were ever vaccinated, 38% received the first dose at or after the 
date of their trigger Pap.  This is consistent with previous analysis of this study 
population.  It was suggested that abnormal cytology prompted vaccination and racial 
disparities in vaccination before and after this time were noted [38].  Significant 
differences in age, race, and insurance status have also been reported for patients with 
vaccine initiation at or after trigger pap [33].                   
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 Our study has several strengths, the first being use of individual HPV type, high-
grade cervical lesion diagnosis, and vaccination history together in one analysis.  
Second, vaccination history was verified and not based solely on self-report.  Third, 
medical records were reviewed for almost every case (approximately 1% of medical 
records are unavailable for review) [50].  Fourth, because high-grade cervical lesions 
are a mandatory reportable condition in the state of Connecticut, our raw data 
represents outcomes in our entire population at risk.  In addition, these conditions are 
reported using a common grading system, helping to ensure accurate disease 
classification. 
 There are some limitations to our study.  First, we had a large amount of missing 
data.  HPV type was not available for 70% of patients and vaccine status was unknown 
for 51% of women.  Race and ethnicity data was also not available for 28% of women 
analyzed.  Missing data resulted in a smaller sample size and more limited time frame 
for analysis.  This also limited ability to analyze trends in HPV type over time to monitor 
vaccine impact.  Second, there is a possibility of selection bias in patient interviews with 
respect to women who were able to be contacted and agreed to the interview and those 
who were not interviewed.  Third, sample size for vaccinated women was very small 
compared to unvaccinated women; however, this may be accurately representative of 
the population and not due to selection bias. 
Lastly, cervical cancer screening guidelines changed in 2010 to discontinue 
screening women under the age of 21 [29].  Data from before and after the change in 
recommendations might no longer be as comparable, as fewer cases may be captured 
now.  However, it is unknown at this time how many providers are following these new 
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guidelines and what the magnitude of difference in screening for women age 18-20 is 
before and after the change in guidelines.  In addition, new 2012 guidelines for 
screening once every three years for women age 21-29, and once every five years for 
women 30 and over may have similar effects [52].  This likely had little impact on the 
current study, but will be something to consider in the future.  It is possible that high 
grade cervical lesion rates will decline in our population in the upcoming years, but 
whether the declines are the result of vaccine impact or changes in screening guidelines 
will need to be examined more closely.   
Our analysis adds to the limited evidence for HPV vaccine effectiveness against 
vaccine type high-grade cervical lesions.  Over time, larger sample size and increased 
vaccine impact should strengthen data for this project.  Vaccine effectiveness estimates 
should become clearer as more vaccinated women reach an age of greater risk for 
these high-grade lesions.  These preliminary results on vaccine effectiveness in our 
population are encouraging and provide support to current recommendations of routine 
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       16/18 Vaccine Type 340 43.15 
     Other High Risk 392 49.75 
     Possible High Risk 44 5.58 
     Low Risk 12 1.52 
Vaccination status 
       Not vaccinated 541 68.65 
     At or after trigger Pap 99 12.56 
     1 year or less before trigger Pap 28 3.55 
     1-2 years before trigger Pap 50 6.35 
     2-3 years before trigger Pap 35 4.44 
     3+ years before trigger Pap 35 4.44 
Age at first vaccine dose   
     Not Vaccinated 541 68.65 
     15-16 5 0.63 
     17-18 20 2.54 
     19-20 48 6.09 
     21-22 75 9.52 
     23-24 60 7.61 
     25-26 34 4.31 
     27 or older 5 0.63 
Age at diagnosis   
     18-20 58 7.36 
     21-24 247 31.35 
     25-29 253 32.11 
     30-34 144 18.27 
     35-39 86 10.91 
Diagnosis   
     CIN2 523 66.37 
     CIN2/3 94 11.93 
     CIN3 167 21.19 
     AIS/AIS+CIN 4 0.51 
Race and ethnicity   
     Hispanic 114 14.47 
     White, not Hispanic 360 45.69 
     Black, not Hispanic 74 9.39 
     Other, not Hispanic 20 2.54 





Table 1. Continued   
 Frequency Percent 
Insurance   
     Private 557 70.69 
     Public 189 23.98 
     Uninsured 14 1.78 
     Other Insurance 2 0.25 
     Insurance NA 26 3.3 
Year of diagnosis   
     2008 295 37.44 
     2009 187 23.73 
     2010 171 21.7 
     2011 122 15.48 
     2012 13 1.65 
Column percentages 









Type n (%) 
Vaccine Type 




    
0.0200 
     Not vaccinated 399 (89.06) 319 (93.82) 718 
      Vaccinated 49   (10.94) 21     (6.18) 70 
      Total 448 340 788 
 Age at vaccination 
    
0.0855 
     Not Vaccinated 294 (65.63) 247 (72.65) 541  
     15-20 48   (10.71) 25     (7.35) 73  
     21+ 106 (23.66) 68   (20.00) 174  
Diagnosis 
     
<.0001 
     CIN2 336 (75.00) 187 (55.00) 523 
      CIN2/3 43     (9.60) 51   (15.00) 94 
      CIN3 69   (15.40) 98   (28.82) 167 
      AIS/AIS+CIN 0            (0) 4       (1.18) 4 
 Age at diagnosis 
          18-20 34     (7.59) 24     (7.06) 58 0.0919 
     21-24 144 (32.14) 103 (30.29) 247 
      25-29 127 (28.35) 126 (37.06) 253 
      30-34 87   (19.42) 57   (16.76) 144 
      35-39 56   (12.50) 30     (8.82) 86 
 Race and ethnicity 
          Hispanic 66   (14.73) 48   (14.12) 114 0.0812 
     White, not Hispanic 186 (41.52) 174 (51.18) 360 
      Black, not Hispanic 48   (10.71) 26     (7.65) 74 
      Other, not Hispanic 13     (2.90) 7       (2.06) 20 
      Race and ethnicity NA 135 (30.13) 85   (25.00) 220 
 Insurance type 
          Private 309 (68.97) 248 (72.94) 557 0.5537 
     Public 113 (25.22) 76   (22.35) 189 
      Uninsured 7       (1.56) 7       (2.06) 14 
      Other Insurance 1       (0.22) 1       (0.29) 2 
      Insurance NA 18     (4.02) 8       (2.35) 26 
 Year of diagnosis 
          2008 167 (37.28) 128 (37.65) 295 0.3880 
     2009 115 (25.67) 72   (21.18) 187 
      2010 89   (19.87) 82   (24.12) 171 
      2011 68   (15.18) 54   (15.88) 122 
      2012 9       (2.01) 4       (1.18) 13 









Figure 2.  Bar graph of changes in non-vaccine type and vaccine type distribution over 
time as a percentage of total specimens, with table of all typed specimens per year 
below   
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Table 3. Unadjusted and adjusted odds ratios for vaccine type  
 
Unadjusted Full model Reduced model 
 
OR (95% CI) OR (95% CI) OR (95% CI) 
Vaccination status    
   Not Vaccinated 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Vaccinated 0.54 (0.32-0.91)** 0.57 (0.30-1.08)* 0.47 (0.27-0.82)*** 
Age at first vaccine dose    
   Not Vaccinated 1.00 (Reference) 1.00 (Reference) 
    15-20 0.62 (0.37-1.04)* 0.74 (0.37-1.49) 
    21+ 0.76 (0.54-1.08) 0.74 (0.48-1.12) 
 Age at diagnosis    
   18-20 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   21-24 1.01 (0.57-1.81) 0.97 (0.50-1.87) 0.99 (0.54-1.80) 
   25-29 1.41 (0.79-2.51) 1.11 (0.55-2.23) 1.23 (0.68-2.24) 
   30-34 0.93 (0.50-1.73) 0.68 (0.32-1.42) 0.80 (0.42-1.52) 
   35-39 0.76 (0.38-1.51) 0.48 (0.21-1.07)* 0.56 (0.27-1.16) 
Diagnosis    
   CIN 2 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   CIN 2/3 2.13 (1.37-3.32)*** 2.13 (1.35-3.35)*** 2.14 (1.36-3.37)*** 
   CIN 3 2.55 (1.79-3.64)*** 2.61 (1.81-3.77)*** 2.65 (1.83-3.82)*** 
   AIS Sample size too small 
Race/ethnicity    
   White, not Hispanic 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Hispanic 0.90 (0.60-1.35) 0.91 (0.59-1.40) 0.93 (0.60-1.43) 
   Black, not Hispanic 0.67 (0.41-1.11) 0.74 (0.43-1.25) 0.76 (0.45-1.29) 
   Other 0.67 (0.26-1.70) 0.68 (0.26-1.80) 0.69 (0.26-1.83) 
Insurance type    
   Private 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Public 0.86 (0.62-1.20) 0.78 (0.54-1.12) 0.78 (0.55-1.13) 
   Uninsured 1.28 (0.44-3.69) 0.95 (0.32-2.86) 1.00 (0.33-2.97) 
   Other 1.28 (0.08-20.52) 1.41 (0.08-23.62) 1.41 (0.08-23.68) 
OR= odds ratio; CI = confidence interval 
*P<0.10; **P<0.05; ***P<0.01 
 
